RxDoctor Payments Data

Lawrence Ginsberg, MD

Internal Medicine · Visalia, CANPI 1326044181

Payments from drug & device makers

$6,351in general payments, 2019–2025

Across 164 payments — averaging $38.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • Lilly USA, LLC$611
  • AstraZeneca$463
  • Novo Nordisk$412
  • Boehringer Ingelheim$396
  • Sumitomo Pharma America, Inc.$305
  • plus $3K from 39 others

What the payments were for

  • Food & beverage$6,325100%
  • Education$260%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,351 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$180,736
Medicare patients
199
Services billed
4,589

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide61$68,363
MounjaroTirzepatide44$54,581
XareltoRivaroxaban46$48,804
Bydureon BciseExenatide Microspheres23$36,981
TrulicityDulaglutide13$29,707
RybelsusSemaglutide12$26,050
EliquisApixaban24$22,354
EntrestoSacubitril/Valsartan13$15,933
Humalog Kwikpen U-200Insulin Lispro13$14,517
JardianceEmpagliflozin14$8,674
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen126$5,599
Advair DiskusFluticasone Propion/Salmeterol20$3,552
PremarinEstrogens, Conjugated13$3,137
Atorvastatin Calcium341$3,081
Levothyroxine Sodium156$2,562

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Levemir$412$95,32284 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog$611$85,18473 claims
Johnson & JohnsonXarelto$167$48,80446 claims
PfizerEliquis, Premarin, Paxlovid$18$26,92150 claims
NovartisEntresto$162$15,93313 claims
Boehringer IngelheimJardiance$396$8,67414 claims
AbbVieSynthroid$209$1,16117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Visalia

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →